Gold-standard evidence and best practice guidance for menstrual cycle-informed clinical care: An overview for clinicians

AI Summary

Hormone sensitivity causes clinically significant cyclical symptoms; PMDD affects approximately 3–8% and PME up to 50–60% among those with mood disorders.
Prospective daily symptom tracking across at least two cycles with biologically anchored cycle phase determination is essential for accurate diagnosis.
Incorporate cycle-informed formulation and adapt evidence-based psychological interventions to predictable luteal phase symptom exacerbations to improve personalised outcomes.

Br J Clin Psychol. 2026 May 20. doi: 10.1111/bjc.70066. Online ahead of print.

ABSTRACT

OBJECTIVES: To synthesize current evidence and provide clinically actionable recommendations for integrating menstrual cycle-related processes-particularly hormone sensitivity, Premenstrual Dysphoric Disorder (PMDD) and Premenstrual Exacerbation (PME)-into psychological assessment, formulation and treatment.

DESIGN: Narrative, clinically oriented review.

METHODS: We integrated findings from experimental, longitudinal and clinical studies on menstrual cycle physiology, hormone sensitivity, PMDD and PME, with a focus on evidence relevant to psychological practice. Emphasis was placed on gold-standard methodologies (e.g., prospective symptom assessment, biologically anchored cycle phase determination) and on translational relevance for clinical decision-making.

RESULTS: A substantial minority of naturally cycling individuals show sensitivity to normative hormonal fluctuations, resulting in clinically significant distress or impairment. PMDD affects approximately 3-8% of menstruating individuals and is characterissed by severe, luteal-phase-specific symptoms and elevated suicidality risk. PME appears even more prevalent, affecting up to 50-60% of individuals with mood disorders. Despite this, menstrual cycle-related symptom patterns are rarely assessed or incorporated into routine care. The literature supports several key clinical strategies: (1) prospective daily symptom tracking across at least two menstrual cycles; (2) cycle-informed case formulations integrating timing and symptom expression; and (3) adaptation of evidence-based interventions to predictable cyclical patterns. Clinician-ready tools and case-based approaches facilitate implementation.

CONCLUSIONS: The menstrual cycle represents a clinically meaningful yet underrecognized source of within-person variability in mental health. Integrating cycle-informed approaches into psychological care can enhance diagnostic precision, improve personalized formulations and optimize treatment outcomes for individuals affected by PMDD and PME.

PMID:42162940 | DOI:10.1111/bjc.70066

Document this CPD